Caris Life Sciences, Inc. (CAI)
NASDAQ (NGS) 
Summary
CAI Chart
Caris Life Sciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 3 | $81 | $53 | -$28 | -34.57% |
| JS Jeremy Szuch MSA Advisors LLC | 19,200 | $513,024 | $337,920 | -$175,104 | -34.13% |
 Point72 Asset Management LP Point72 Asset Management LP | 918,331 | $24.78M | $16.14M | -$8.63M | -34.84% |
 Joseph Castro Nuveen LLC | 663,578 | $12.14M | $11.44M | -$697,161.04 | -5.74% |
| TC Thomas Cagna Sandia Investment Management LP | 23,600 | $634,492 | $408,171.44 | -$226,320.56 | -35.67% |
Caris Life Sciences, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 105.36 | $1,701.62 | $1,839.65 | $138.03 | 8.11% |
Caris Life Sciences, Inc. (CAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Caris Life Sciences, Inc. ever had a stock split?
Caris Life Sciences, Inc. Profile
| - Industry | - Sector | Dr. David Dean Halbert M.D. CEO | NASDAQ (NGS) Exchange | 142152107 CUSIP |
| United States Country | 1,769 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Caris Life Sciences is a pioneering AI-driven precision medicine company dedicated to transforming the healthcare landscape through meticulous molecular profiling and sophisticated machine learning techniques. Specializing in the in-depth analysis of cancer at the molecular level, Caris employs advanced methods such as whole exome and whole transcriptome sequencing using patient tissue and blood samples. The company's innovative approach has enabled it to cultivate one of the world's largest multimodal clinico-genomic databases, which integrates genomic, transcriptomic, and proteomic data along with clinical outcomes, encompassing over 740,000 matched patient records.
Founded in 2008 and headquartered in Irving, Texas, Caris Life Sciences operates on an international scale, with offices in prominent medical and research hubs. The company's commitment to precision medicine is evident in its array of solutions that empower oncologists and patients, providing essential molecular information that supports therapy selection, enhances drug development, and fosters early disease detection.
Products and Services
- MI Profile
MI Profile is Caris’ flagship tissue-based profiling solution that utilizes comprehensive molecular profiling techniques to analyze tumor biology. This service aids in understanding the specific characteristics of a patient’s cancer and helps guide personalized treatment plans tailored to individual patient needs. - Caris Assure
Caris Assure offers blood-based analysis for cancer assessment, leveraging advanced techniques to evaluate the molecular landscape of cancer through liquid biopsies. This non-invasive service allows clinicians to gather important molecular data without the need for invasive tissue collection, facilitating easier monitoring of patients’ conditions over time. - Caris Detect
Caris Detect is a multi-cancer early detection assay that employs ultra-deep whole genome sequencing to identify signs of cancer at its earliest stages. This innovative blood test is designed to provide oncologists with critical insights that can lead to prompt diagnosis and timely intervention, potentially improving patient outcomes.
